Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma

The BCL-2-specific inhibitor, ABT-199 (venetoclax) has exhibited remarkable clinical activity in nearly all cases of chronic lymphocytic leukemia. In contrast, responses are usually much less in diffuse large B-cell lymphoma (DLBCL), despite high level expression of BCL-2 in over 40% of cases, indic...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Victoria M., Dietz, Anna, Henz, Kristina, Bruecher, Daniela, Jackson, Ross, Kowald, Lisa, van Wijk, Sjoerd J.L., Jayne, Sandrine, Macip, Salvador, Fulda, Simone, Dyer, Martin J.S., Vogler, Meike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395267/
https://www.ncbi.nlm.nih.gov/pubmed/31601689
http://dx.doi.org/10.3324/haematol.2019.220525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395267/
https://www.ncbi.nlm.nih.gov/pubmed/31601689
http://dx.doi.org/10.3324/haematol.2019.220525

Ejemplares similares